Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery

The anti-atherosclerotic effect of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors at doses insufficient to lower serum cholesterol was investigated in rabbit femoral artery denuded by balloon catheter. Fluvastatin and pravastatin were given orally at doses of 4 and 8 mg/kg per day, respectively, for 2 weeks after the catheterization. There was little change in serum cholesterol, triglyceride and phospholipid by chronic treatment with the drugs. The cross-sectional area of the intima, expressed as relative values to media ( I M ratio), was increased by the catheterization, showing intimal thickening in the denuded arteries. The I M ratio was reduced by fluvastatin but not pravastatin: 0.327 ± 0.060 for control, 0.116 ± 0.035 for 4 mg/kg fluvastatin, 0.088 ± 0.027 for 8 mg/kg fluvastatin and 0.22 ± 0.069 for 8 mg/kg pravastatin. Fluvastatin (8 mg/kg)-induced effect on the I M ratio, was prevented by the combined administration with 40 mg/kg per day mevalonate, a metabolite in the HMG-CoA reductase pathway. These results suggest that fluvastatin inhibits intimal thickening after catheterization-induced injury through percutaneous transluminal coronary angioplasty (PTCA) and that the inhibition is presumably attributed to reduced migration and proliferation of smooth muscle cells but not secondarily to a lowering of serum lipid.